AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients

PRESS RELEASEAB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH ...

AB Science provides an update on its clinical development program.

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III ...
ALS News Today

Masitinib trial insurance offers a safety net for ALS research

Masitinib is an experimental oral therapy for ALS that's aimed at slowing disease progression. AB Science secured insurance ...
Seeking Alpha

Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB)

Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotech ...